[1] Stella VJ,Nti-Addae KW.Prodrug strategies to overcome poor water solubility[J]. Adv Drug Deliv Rev, 2007, 59(7):677-694.
[2] Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system:the scientific basis for biowaiver extensions[J]. Pharm Res, 2002,19(7):921-925.
[3] Giliyar C, Fikstad DT, Tyavanagimatt S. Challenges and opportunities in oral delivery of poorly water-soluble drugs[J]. Drug Deliv Technol,2006,6(1):57-63.
[4] Hauss DJ. Oral lipid-based formulations[J]. Adv Drug Deliv Rev, 2007,59(7):667-676.
[5] Colin WP. Formulation of poorly water-soluble drugs for oral administration:physicochemical and physiological issues and the lipid formulation classification system[J]. Eur J Pharm,2006, 29(3-4):278-287.
[6] Pouton CW. Formulation of poorly water soluble drugs for oral administration:physicochemical issues and the lipid formulation classification system[J]. Eur J Pharm, 2006(29):278-287.
[7] Hamberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs[J]. Adv Drug Deliv Rev, 1997, 25:103-108.
[8] Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration:materials, methods and strategies[J]. Adv Drug Deliv Rev, 2008, 60:625-637.
[9] Setbia S, Squillante E. Solid dispersion:revival with greater possibilities and application in oral drug delivery[J]. Crit Rev Ther Drug Carrier Syst, 2003,20(2-3):215-247.
[10] 安富荣, 苏德森. 生物技术药物的脂质体给药系统研究进展[J]. 中国生化药物杂志, 2003, 24(4):207-209.
[11] 张 宁, 王海学, 钱思源. 浅谈细胞毒类抗肿瘤药物脂质体制剂的研究思路[J]. 中国新药杂志, 2006,15(21):1805-1807.
[12] Porter CJH, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid based delivery systems[J]. Adv Drug Deliv Rev, 2008, 60:673-691.
[13] Zangenberg NH, Mullertz A, Kristensen HG, et al. A dynamic in virto lipolysis model.Ⅰ:controlling the rate of lipolysis by continuous addition of calcium[J]. Eur J Pharm, 2001, 14:115-122.
[14] Kaukonen AM, Boyd BJ, Porter CJH, et al. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulation[J]. Pharm Res, 2004,21:245-253.
[15] Zangenberg NH, Mullertz A, Kristensen HG, et al. A dynamic in virto lipolysis model. Ⅱ:evaluation of the model[J].Eur J Pharm, 2001, 14:237-244.
[16] Larsen A, Sassene P, Mullertz A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems[J]. Int J Pharm, 2011, 417:245-255.
[17] Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize of poorly water soluble drugs:correlation with in vivo data and the relationship to intra enterocyte processes in rats[J]. Pharm Res, 2006, 23(9):2165-2174.
[18] Sek L, Porter CJH, Charman WN, et al. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products,by HPLC coupled with in situ densitometric analysis[J]. J Pharm Biomed Anal, 2001, 25(3-4):651-661.
[19] Fatouros DG, Nielsen FS, Douroumis D, et al. In vitro-in vivo correlations of self emulsifying drug delivery systems combining the dynamic lipolysis model and neuro fuzzy networks[J]. Eur J Pharm, 2008, 69:887-898.
[20] 宦 娣, 易 涛, 刘 颖, 等. 微粉硅胶对固体自微乳化给药系统小肠吸收的影响[J]. 药学学报, 2011, 46 (4):466-471.
[21] 刘 颖, 肖 璐, 何吉奎, 等. 脂质制剂体外动态肠吸收模型的建立及评价[J]. 药学学报, 2011, 46(8):983-989.
[22] 刘 颖, 易 涛, 宦 娣, 等. 利用体外脂解模型评价Ⅰ型脂质制剂[J]. 药学学报, 2010, 45 (10):1307-1311.